Renovaro Biosciences Inc - Asset Resilience Ratio
Renovaro Biosciences Inc (RENB) has an Asset Resilience Ratio of 4.71% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Renovaro Biosciences Inc's Asset Resilience Ratio has changed over time. Check Renovaro Biosciences Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Renovaro Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Renovaro Biosciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $387.85K | 4.71% |
| Total Liquid Assets | $387.85K | 4.71% |
Asset Resilience Insights
- Limited Liquidity: Renovaro Biosciences Inc maintains only 4.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Renovaro Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Renovaro Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Renovaro Biosciences Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Renovaro Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.24% | $387.85K | $163.13 Million | -- |
| 2024-06-30 | 0.00% | $0.00 | $163.13 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $179.88 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $182.50 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $4.52 Million | -- |
| 2015-06-30 | 38.73% | $2.03 Million | $5.24 Million | -- |
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more